Insulin Facilitates the Recovery of Myocardial Contractility and Conduction during Cardiac Compression in Rabbits with Bupivacaine-Induced Cardiovascular Collapse
Bupivacaine inhibits cardiac conduction and contractility. Insulin enhances cardiac repolarization and myocardial contractility. We hypothesizes that insulin therapy would be effective in resuscitating bupivacaine-induced cardiac toxicity in rabbits. Twelve rabbits were tracheally intubated and midline sternotomy was performed under general anesthesia. Cardiovascular collapse (CVC) was induced by an IV bolus injection of bupivacaine 10?mg/kg. The rabbits were treated with either saline (control) or insulin injection, administered as a 2?U/kg bolus. Internal cardiac massage was performed until the return of spontaneous circulation (ROSC) and the time to the return of sinus rhythm (ROSR) was also noted in both groups. Arterial blood pressure, and electrocardiography were continuously monitored for 30?min and plasma bupivacaine concentrations at every 5?min. The ROSC, ROSR and normalization of QRS duration were attained faster in the insulin-treated group than in the control group. At the ROSC, there was a significant difference in bupivacaine concentration between two groups. Insulin facilitates the return of myocardial contractility and conduction from bupivacaine-induced CVC in rabbits. However, recovery of cardiac conduction is dependent mainly on the change of plasma bupivacaine concentrations. 1. Introduction Resuscitation following bupivacaine-induced cardiovascular collapse (CVC) is difficult and often resistant to conventional treatment [1]. Bupivacaine blocks cardiac Na+ channel [2, 3] and transient outward K+ currents [4]. Increased ECG intervals [5] and decreased R-wave amplitude in lead II [6] are shown by the bupivacaine infusion. Bupivacaine also decreases the maximal rate of depolarization in Purkinje fibers [7]. Alteration of Ca++ recruitment from sarcoplasmic reticulum [8] and mitochondrial ATP production [9] are related to the deterioration of myocardial contractility by bupivacaine. Previous experiments have shown that insulin might be effective in reversing bupivacaine-induced cardiac depression probably by enhancing transient outward K+ current, Ca++ transport activity of sarcoplasmic reticulum, and improving myocardial energetics [5, 10]. In contrast, Stehr et al. demonstrate that insulin has a significant positive inotropic effect without affecting electrophysiologic parameters at a fixed bupivacaine concentration in an in vitro study [11]. Because bupivacaine impairs ventricular conduction in a dose-dependent manner and QRS widening has been shown as a function of bupivacaine concentration in an isolated rabbit heart model [12], we
References
[1]
W. B. Long, S. Rosenblum, and I. P. Grady, “Successful resuscitation of bupivacaine-induced cardiac arrest using cardiopulmonary bypass,” Anesthesia & Analgesia, vol. 69, no. 3, pp. 403–406, 1989.
[2]
S. Reiz and S. Nath, “Cardiotoxicity of local anaesthetic agents,” British Journal of Anaesthesia, vol. 58, no. 7, pp. 736–746, 1986.
[3]
C. W. Clarkson and L. M. Hondeghem, “Mechanism for bupivacaine depression of cardiac conduction: fast block of sodium channels during the action potential with slow recovery from block during diastole,” Anesthesiology, vol. 62, no. 4, pp. 396–405, 1985.
[4]
N. A. Castle, “Bupivacaine inhibits the transient outward K+ current but not the inward rectifier in rat ventricular myocytes,” Journal of Pharmacology and Experimental Therapeutics, vol. 255, no. 3, pp. 1038–1046, 1990.
[5]
H. S. Cho, J. J. Lee, I. S. Chung, B. S. Shin, J. A. Kim, and K. H. Lee, “Insulin reverses bupivacaine-induced cardiac depression in dogs,” Anesthesia & Analgesia, vol. 91, no. 5, pp. 1096–1102, 2000.
[6]
E. U. M. Nystr?m, J. E. Heavner, and C. W. Buffington, “Blood pressure is maintained despite profound myocardial depression during acute bupivacaine overdose in pigs,” Anesthesia & Analgesia, vol. 88, no. 5, pp. 1143–1148, 1999.
[7]
P. Arlock, “Actions of three local anaesthetics: lidocaine, bupivacaine and ropivacaine on guinea pig papillary muscle sodium channels(Vmax),” Pharmacology and Toxicology, vol. 63, no. 2, pp. 96–104, 1988.
[8]
H. Komai and A. J. Lokuta, “Interaction of bupivacaine and tetracaine with the sarcoplasmic reticulum Ca2+ release channel of skeletal and cardiac muscles,” Anesthesiology, vol. 90, no. 3, pp. 835–843, 1999.
[9]
X. Sun and K. D. Garlid, “On the mechanism by which bupivacaine conducts protons across the membranes of mitochondria and liposomes,” Journal of Biological Chemistry, vol. 267, no. 27, pp. 19147–19154, 1992.
[10]
J. T. Kim, C. W. Jung, and K. H. Lee, “The effect of insulin on the resuscitation of bupivacaine-induced severe cardiovascular toxicity in dogs,” Anesthesia & Analgesia, vol. 99, no. 3, pp. 728–733, 2004.
[11]
S. N. Stehr, A. Pexa, S. Hannack et al., “Insulin effects on myocardial function and bioenergetics in L-bupivacaine toxicity in the isolated rat heart,” European Journal of Anaesthesiology, vol. 24, no. 4, pp. 340–346, 2007.
[12]
L. Simon, N. Kariya, A. Edouard, D. Benhamou, and J. X. Mazoit, “Effect of bupivacaine on the isolated rabbit heart: developmental aspect on ventricular conduction and contractility,” Anesthesiology, vol. 101, no. 4, pp. 937–944, 2004.
[13]
Y. Mio, N. Fukuda, Y. Kusakari, Y. Tanifuji, and S. Kurihara, “Bupivacaine attenuates contractility by decreasing sensitivity of myofilaments to Ca2+ in rat ventricular muscle,” Anesthesiology, vol. 97, no. 5, pp. 1168–1177, 2002.
[14]
M. P. Gupta, I. R. Innes, and N. S. Dhalla, “Characterization of insulin receptors in cardiac sarcolemmal and sarcoplasmic reticular membranes,” Journal of Cardiovascular Pharmacology, vol. 10, no. 3, pp. 259–267, 1987.
[15]
K. Zierler and F. S. Wu, “An early outward transient K+ current that depends on a preceding Na+ current and is enhanced by insulin,” Pflugers Archiv European Journal of Physiology, vol. 422, no. 3, pp. 267–272, 1992.
[16]
N. A. Paradis, G. B. Martin, E. P. Rivers et al., “Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation,” Journal of the American Medical Association, vol. 263, no. 8, pp. 1106–1113, 1990.
[17]
P. Lacombe, G. Blaise, D. Loulmet, and C. Hollmann, “Electrophysiologic effects of bupivacaine in the isolated rabbit heart,” Anesthesia & Analgesia, vol. 72, no. 1, pp. 62–69, 1991.
[18]
D. M. Kotelko, S. M. Shnider, P. A. Dailey, et al., “Bupivacaine-induced cardiac arrhythmias in sheep,” Anesthesiology, vol. 60, no. 1, pp. 10–18, 1984.
[19]
B. N. Singh and E. M. Williams, “Effect of altering potassium concentration on the action of lidocaine and diphenylhydantoin on rabbit atrial and ventricular muscle,” Circulation Research, vol. 29, no. 3, pp. 286–295, 1971.
[20]
H. S. Cho, J. A. Kim, S. Lee, and K. H. Lee, “The influence of serum potassium change on bupivacaine-induced cardiac toxicity in dogs with normal serum potassium concentration,” Korean Journal of Anesthesiology, vol. 39, no. 1, pp. 119–123, 2000.
[21]
H. S. Feldman, G. R. Arthur, and B. G. Covino, “Comparative systemic toxicity of convulsant and supraconvulsant doses of intravenous ropivacaine, bupivacaine, and lidocaine in the conscious dog,” Anesthesia & Analgesia, vol. 69, no. 6, pp. 794–801, 1989.